J. Mitrović

Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach

V. Dobričić, S. Savić, D. Randjelović, 2021, Pharmaceutics.

The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions

V. Papadimitriou, A. Xenakis, S. Savić, 2022, Pharmaceutics.

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

I. Nikolić, S. Savić, M. Savić, 2023, Pharmaceutics.

Behavioural interaction of pyrazoloquinolinone positive allosteric modulators at α6GABAA receptors and diazepam in rats: Anti‐diazepam‐induced ataxia action as a structure‐dependent feature

S. Savić, M. Savić, D. Knutson, 2022, Basic & clinical pharmacology & toxicology.

Curcumin Loaded PEGylated Nanoemulsions Designed for Maintained Antioxidant Effects and Improved Bioavailability: A Pilot Study on Rats

V. Stevanovic, I. Nikolić, J. Antić-Stanković, 2021, International journal of molecular sciences.

Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: formulation approach toward improved in vivo performance.

V. Dobričić, S. Savić, D. Randjelović, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: physicochemical, structural and pharmacokinetic performances.

V. Dobričić, S. Savić, Milos Petkovic, 2023, International journal of pharmaceutics.

Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): process parameters and lyoprotectant selection through the stability study.

S. Savić, O. Planinšek, A. Kremenović, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices f

J. Witkin, P. Scholze, L. Arnold, 2024, ACS chemical neuroscience.